What is No­var­tis with­out San­doz? Vas Narasimhan is 'pa­tien­t' as new com­pa­ny takes form

Vas Narasimhan is stead­fast on his mis­sion to re­shape No­var­tis, culling a few pro­grams last quar­ter and mak­ing the fi­nal arrange­ments to spin off gener­ics unit San­doz. But make no mis­take — he’s al­so “will­ing to be pa­tient.”

While the chief ex­ec­u­tive said on the com­pa­ny’s Q3 call Tues­day that he’s still look­ing for deals in the sub-$3 bil­lion to $4 bil­lion range and a “broad range of li­cens­ing op­por­tu­ni­ties,” he made clear he won’t jump for just any­thing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER